EA201391127A1 - C-17 и c-3 модифицированные тритерпеноиды с ингибиторной активностью созревания вич - Google Patents

C-17 и c-3 модифицированные тритерпеноиды с ингибиторной активностью созревания вич

Info

Publication number
EA201391127A1
EA201391127A1 EA201391127A EA201391127A EA201391127A1 EA 201391127 A1 EA201391127 A1 EA 201391127A1 EA 201391127 A EA201391127 A EA 201391127A EA 201391127 A EA201391127 A EA 201391127A EA 201391127 A1 EA201391127 A1 EA 201391127A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitor activity
hiv maturation
compounds
modified triterpenoids
hiv
Prior art date
Application number
EA201391127A
Other languages
English (en)
Other versions
EA022470B1 (ru
Inventor
Алисия Регуэйро-Рен
Чжэн Лю
Джейкоб Свидорски
Ны Син
Брайан Ли Венаблс
Син-Юэнь Сит
Янь Чэнь
Цзе Чэнь
Николас А. Минвелл
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of EA201391127A1 publication Critical patent/EA201391127A1/ru
Publication of EA022470B1 publication Critical patent/EA022470B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Описаны соединения, имеющие лекарственные свойства и оказывающие биовоздействие, их фармацевтические композиции и способы применения. В частности, С-17 и С-3 модифицированные тритерпеноиды, которые обладают уникальной противовирусной активностью, описаны в качестве ингибиторов созревания ВИЧ, которые представлены соединениями формул I, II и III:Эти соединения являются пригодными для лечения ВИЧ и СПИД.
EA201391127A 2011-01-31 2012-01-27 C-17 и c-3 модифицированные тритерпеноиды с ингибиторной активностью созревания вич EA022470B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161437893P 2011-01-31 2011-01-31
PCT/US2012/022852 WO2012106190A1 (en) 2011-01-31 2012-01-27 C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity

Publications (2)

Publication Number Publication Date
EA201391127A1 true EA201391127A1 (ru) 2013-12-30
EA022470B1 EA022470B1 (ru) 2016-01-29

Family

ID=45567147

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391127A EA022470B1 (ru) 2011-01-31 2012-01-27 C-17 и c-3 модифицированные тритерпеноиды с ингибиторной активностью созревания вич

Country Status (24)

Country Link
US (3) US8846647B2 (ru)
EP (1) EP2670765B1 (ru)
JP (1) JP6001560B2 (ru)
KR (1) KR101886467B1 (ru)
CN (1) CN103429607B (ru)
AR (1) AR085053A1 (ru)
AU (1) AU2012212509B2 (ru)
BR (1) BR112013019419A2 (ru)
CA (1) CA2826113C (ru)
CL (1) CL2013002185A1 (ru)
CO (1) CO6751275A2 (ru)
EA (1) EA022470B1 (ru)
ES (1) ES2653847T3 (ru)
IL (1) IL227678B (ru)
MA (1) MA34909B1 (ru)
MY (1) MY162186A (ru)
PE (1) PE20141152A1 (ru)
PT (1) PT2670765T (ru)
SG (1) SG192144A1 (ru)
TN (1) TN2013000321A1 (ru)
TW (1) TWI628188B (ru)
UY (1) UY33886A (ru)
WO (1) WO2012106190A1 (ru)
ZA (1) ZA201306546B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2716502C2 (ru) * 2016-02-04 2020-03-12 ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД C-3 и C-17 модифицированные тритерпеноиды в качестве ингибиторов ВИЧ-1

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0911105B1 (pt) 2008-04-18 2022-11-08 Reata Pharmaceuticals, Inc Compostos contendo um farmacóforo anti-inflamatório, composição farmacêutica, bem como seus usos
LT2276493T (lt) 2008-04-18 2019-01-10 Reata Pharmaceuticals, Inc. Antioksidaciniai uždegimo moduliatoriai: oleanolio rūgšties dariniai su amino ir kitomis modifikacijomis c-17
DK2271658T3 (en) 2008-04-18 2017-02-06 Reata Pharmaceuticals Inc ANTIOXIDANT INFLAMMATION MODULATORS: C-17 HOMOLOGED OLEANOLIC ACID DERIVATIVES
EP2279197B1 (en) 2008-04-18 2014-11-05 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
ES2653717T3 (es) 2010-12-17 2018-02-08 Reata Pharmaceuticals, Inc. Pirazolil- y pirimidinil-enonas tricíclicas como moduladores antioxidantes de la inflamación
MX2013008359A (es) * 2011-01-31 2013-08-27 Bristol Myers Squibb Co Aminas de c-28 de derivados de acido betulinico modificado de c-3 como inhibidores de la maduracion del virus de inmunodeficiencia humana.
EA026847B1 (ru) 2011-03-11 2017-05-31 Рита Фармасьютикалз, Инк. C4-монометилтритерпеноидные производные и способы их применения
US8754069B2 (en) 2011-09-21 2014-06-17 Bristol-Myers Squibb Company Betulinic acid derivatives with antiviral activity
US8906889B2 (en) * 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
CA2869783C (en) 2012-04-27 2022-06-21 Reata Pharmaceuticals, Inc. 2.2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
RU2644160C2 (ru) * 2012-08-15 2018-02-08 Глаксо Груп Лимитед Химический способ
CA2882418C (en) 2012-09-10 2021-05-04 Reata Pharmaceuticals, Inc. C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
EA027371B1 (ru) * 2013-02-06 2017-07-31 Бристол-Майерс Сквибб Компани C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
AU2014218754B2 (en) 2013-02-25 2017-04-20 VIIV Healthcare UK (No.5) Limited C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of HIV
JP6568202B2 (ja) 2014-04-11 2019-08-28 ヴィーブ ヘルスケア ユーケー（ナンバー４）リミテッド ハロアルキル置換基を有する非芳香族環により３位で置換されている、ｈｉｖ成熟阻害活性を有するトリテルペノイド
US9920090B2 (en) 2014-06-19 2018-03-20 VIIV Healthcare UK (No.5) Limited Betulinic acid derivatives with HIV maturation inhibitory activity
US9969767B2 (en) 2014-11-14 2018-05-15 VIIV Healthcare UK (No.5) Limited Oxolupene derivatives
AU2015346311A1 (en) * 2014-11-14 2017-06-08 Viiv Healthcare UK (No5) Limited C17-aryl substituted betulinic acid analogs
CN107428798A (zh) * 2015-04-14 2017-12-01 Viiv保健英国第四有限公司 生产hiv成熟抑制剂的方法
RU2018105352A (ru) 2015-07-28 2019-08-29 ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед Производные бетулина для предупреждения или лечения ВИЧ-инфекций
JP2018521093A (ja) 2015-07-28 2018-08-02 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｈｉｖ感染を予防または治療するためのベツイン誘導体
WO2017025901A1 (en) * 2015-08-11 2017-02-16 Hetero Research Foundation Novel c28-analogues with c3-modifications of triterpene derivatives as hiv inhibitors
KR20180061251A (ko) 2015-09-23 2018-06-07 리아타 파마슈티컬즈, 아이엔씨. Il-17의 저해를 위한 c4-변형된 올레아놀산 유도체 및 다른 용도
RU2018112958A (ru) 2015-09-24 2019-10-28 ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед Соединения с ингибирующей созревание ВИЧ активностью
TW201726133A (zh) 2015-11-20 2017-08-01 Ｖｉｉｖ醫療保健英國（Ｎｏ‧４）有限公司 Ｈｉｖ成熟抑制劑調配物
US20190023733A1 (en) 2016-01-20 2019-01-24 Glaxosmithkline Intellectual Property (No.2) Limited Amine derivatives of lupanes with hiv maturation inhibitory activity
EP3478703A1 (en) * 2016-06-30 2019-05-08 ViiV Healthcare UK (No.5) Limited Triterpenoid inhibitors of human immunodeficiency virus replication
WO2018044822A1 (en) * 2016-08-31 2018-03-08 Viiv Healthcare Company Combinations and uses and treatments thereof
CA3071992A1 (en) 2017-08-04 2019-03-28 Ardelyx, Inc. Glycyrrhetinic acid derivatives for treating hyperkalemia
JP6977474B2 (ja) * 2017-10-23 2021-12-08 東京エレクトロン株式会社 半導体装置の製造方法
JP6926939B2 (ja) * 2017-10-23 2021-08-25 東京エレクトロン株式会社 半導体装置の製造方法
EP4321164A3 (en) 2018-04-24 2024-04-17 ViiV Healthcare UK (No.5) Limited Compounds with hiv maturation inhibitory activity
PL237998B1 (pl) 2018-05-28 2021-06-28 Narodowy Inst Lekow Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie
EP3921327B1 (en) 2019-02-07 2023-04-05 Ardelyx, Inc. Glycyrrhetinic acid derivatives for use in treating hyperkalemia
HRP20231582T1 (hr) 2019-02-11 2024-03-15 Hetero Labs Limited Novi derivati triterpena kao inhibitori hiv-a
GB2598300A (en) * 2020-08-21 2022-03-02 Univ Durham Cross-linking method and applications in bioconjugation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
WO2004089357A2 (en) 2003-04-02 2004-10-21 Regents Of The University Of Minnesota Anti-fungal formulation of triterpene and essential oil
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20050239748A1 (en) 2004-03-17 2005-10-27 Panacos Pharmaceuticals, Inc. Pharmaceutical salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid
TW200628161A (en) * 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
US8067620B2 (en) 2005-05-04 2011-11-29 Medicines For Malaria Venture Mmv Dispiro 1,2,4-trioxolane antimalarials
WO2008127364A2 (en) * 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
US20110144069A1 (en) 2006-10-16 2011-06-16 Myriad Genetics, Incorporated Compounds for treating viral infections
AU2009214779A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. Novel 17beta lupane derivatives
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
US8802661B2 (en) * 2010-06-04 2014-08-12 Bristol-Myers Squibb Company C-28 amides of modified C-3 betulinic acid derivatives as HIV maturation inhibitors
WO2011153315A1 (en) * 2010-06-04 2011-12-08 Bristol-Myers Squibb Company Modified c-3 betulinic acid derivatives as hiv maturation inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2716502C2 (ru) * 2016-02-04 2020-03-12 ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД C-3 и C-17 модифицированные тритерпеноиды в качестве ингибиторов ВИЧ-1

Also Published As

Publication number Publication date
PE20141152A1 (es) 2014-09-22
CL2013002185A1 (es) 2013-12-27
JP2014503595A (ja) 2014-02-13
IL227678B (en) 2018-04-30
CA2826113A1 (en) 2012-08-09
JP6001560B2 (ja) 2016-10-05
AU2012212509B2 (en) 2016-01-21
EP2670765B1 (en) 2017-10-18
US8846647B2 (en) 2014-09-30
EA022470B1 (ru) 2016-01-29
TN2013000321A1 (en) 2015-01-20
AR085053A1 (es) 2013-08-07
MA34909B1 (fr) 2014-02-01
AU2012212509A1 (en) 2013-09-19
NZ614871A (en) 2014-06-27
US20160151387A1 (en) 2016-06-02
WO2012106190A1 (en) 2012-08-09
ZA201306546B (en) 2015-03-25
CN103429607B (zh) 2016-02-17
CN103429607A (zh) 2013-12-04
US20130035318A1 (en) 2013-02-07
ES2653847T3 (es) 2018-02-09
SG192144A1 (en) 2013-08-30
BR112013019419A2 (pt) 2019-12-03
UY33886A (es) 2012-07-31
EP2670765A1 (en) 2013-12-11
KR20140016279A (ko) 2014-02-07
US20140343000A1 (en) 2014-11-20
PT2670765T (pt) 2018-01-08
MY162186A (en) 2017-05-31
TW201309717A (zh) 2013-03-01
CA2826113C (en) 2018-09-04
CO6751275A2 (es) 2013-09-16
TWI628188B (zh) 2018-07-01
IL227678A0 (en) 2013-09-30
KR101886467B1 (ko) 2018-08-07

Similar Documents

Publication Publication Date Title
EA201391127A1 (ru) C-17 и c-3 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
PH12020550552A1 (en) Inhibitors of hepatitis c virus
EA201270800A1 (ru) С-28 амиды модифицированных производных с-3 бетулиновой кислоты в качестве ингибиторов созревания вич
CY1121150T1 (el) Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας
EA201270780A1 (ru) С-3 модифицированные производные бетулиновой кислоты в качестве ингибиторов созревания вич
EA201491531A1 (ru) C-3 циклоалкенил тритерпеноиды, ингибирующие созревание вич
EA201492016A1 (ru) C-17 бициклические амины тритерпеноидов с ингибиторной активностью созревания вич
UA111770C2 (uk) Інгібітори бромдомену
MX2015010354A (es) Derivados de acido betulinico modificados con aquilo c-3 y alquenilo utiles en el tratamiento de virus de inmunodeficiencia humana (vih).
EA201391098A1 (ru) C-28-амины c-3-модифицированных производных бетулиновой кислоты в качестве ингибиторов созревания вич
MD20140135A2 (ru) Макроциклические ингибиторы вирусов семейства Flaviviridae
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
IN2014MN02652A (ru)
EA201492205A1 (ru) Макроциклические ингибиторы вирусов flaviviridae
UA111841C2 (uk) Сполуки бензотіазолу та їх фармацевтичне застосування
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
EA201291300A1 (ru) Производные нафт-2-илуксусной кислоты для лечения спида
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
UA113956C2 (xx) Похідні піримідину для лікування вірусних інфекцій
UA108221C2 (uk) Похідні тіофен-2-карбонової кислоти як інгібітори вірусів flaviviridae
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
IN2015DN01119A (ru)
MX2014002936A (es) Nuevos derivados de acido betulinico con actividad antiviral.
EA201791807A1 (ru) Новый тритерпенон по с-3 с обратными амидными производными по с-17 в качестве ингибиторов вич
EA201891649A1 (ru) C-3 и c-17 модифицированные тритерпеноиды в качестве ингибиторов вич-1

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

PC4A Registration of transfer of a eurasian patent by assignment